Navigation Links
Endologix Announces FDA Approval of AFX™ Endovascular AAA System
Date:6/15/2011

g technology.

John McDermott, President and Chief Executive Officer of Endologix, commented, "Achieving FDA approval for the AFX System is an important milestone for Endologix and for the physicians and patients we serve. The advances incorporated into the AFX System will give physicians even more confidence and precision in treating a wide range of AAA anatomies. The SVS annual meeting provides an ideal venue to begin educating physicians on the new system, which we expect to be commercially available within a couple of months following the necessary sales force training and inventory build."

In addition to AFX, the Company's complete product portfolio will be highlighted at the SVS Annual Meeting.  This includes the investigational Nellix® Endovascular System and the Ventana™ Fenestrated Stent Graft System, both of which will be featured in symposia at SVS.

About Endologix, Inc.Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.  

Forward-Looking Statements Except for historical information contained herein, this news release contains forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to dif
'/>"/>

SOURCE Endologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Endologix Comments on Alleged Patent Infringement
2. Endologix Responds to Alleged Patent Infringement
3. Endologix to Report Third Quarter 2009 Financial Results on October 27, 2009
4. Endologix Reports 47% Third Quarter 2009 Revenue Growth
5. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
6. Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology
7. Endologix Receives CE Mark Approval for Expanded Line of Powerlink Products and PowerFit Aortic Extensions
8. Endologix to Report Third Quarter 2010 Financial Results on October 27, 2010
9. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
10. Endologix to Present at Oppenheimer 21st Annual Healthcare Conference
11. Endologix Reports 30% Third Quarter 2010 Revenue Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015  ArmaGen, Inc., a privately ... to treat severe neurological disorders, announced today that ... multi-center Phase 1/2a clinical trial of AGT-181 in ... AGT-181 is an investigational enzyme ... I. The most severe form of MPS I, ...
(Date:9/2/2015)... -- Elekta, a global cancer management company, will ... 6:30-8:30 p.m., at Elekta,s North American headquarters in ... will feature Professional BMX athlete, Josh Perry , who ... Leksell Gamma Knife®, Elekta,s radiosurgery system for treating brain disorders. ... diagnosed in Georgia in 2015 and ...
(Date:9/2/2015)... Mass. and TORONTO ... Biotechnology Corporation ( www.generex.com ) (OTCQB: GNBT) ... to implement a buccal cannabis co-development arrangement ... has been formalized. Generex and ... and Technology Licensing Agreement.  Pursuant to the ...
Breaking Medicine Technology:ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 2Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 3Generex Announces Formalization of Buccal Cannabis Co-Development Plan 2Generex Announces Formalization of Buccal Cannabis Co-Development Plan 3
... , , INDIANAPOLIS, Nov. 16 ... Chairman, President and Chief Executive Officer John Lechleiter today presented ... check represents the contributions of Lilly,s U.S. employees and retirees ... funds were raised for the Central Indiana chapter and other ...
... , - Used during coronary angioplasty plus stenting, in ... new reversible blood thinner did not have a significantly ... all-cause mortality, heart attack and need for new procedures ... drug significantly lessened the risk for two pre-specified single ...
Cached Medicine Technology:Lilly Surpasses United Way 2009 Campaign Goal 2Lilly Surpasses United Way 2009 Campaign Goal 3American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 2American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 3
(Date:9/2/2015)... ... September 02, 2015 , ... Healthegy, a leading ... two leaders who will deliver keynote presentations at the upcoming Digital Healthcare Innovation ... Hotel in Boston. , Larry Renfro, CEO of Optum, will deliver the morning ...
(Date:9/2/2015)... ... 2015 , ... The Western Connecticut Health Network (WCHN) has ... to establish the Abraham and Mildred Goldstein Endowment Fund for Ovarian Cancer Research. ... known gynecologic oncologist Thomas J. Rutherford, MD, PhD as its network physician director ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... data collection, cloud analytics and workflow solutions today announced the September 2015 ... researchers to participate in interactive programs in which ERT scientists and partner ...
(Date:9/2/2015)... Waltham, MA (PRWEB) , ... September 02, 2015 ... ... often get swamped with a large stream of mixed documents that include EOBs, ... the various documents, while extracting the data needed to reconcile their billing, with ...
(Date:9/2/2015)... ... September 02, 2015 , ... Michael Elliot Media announces a ... plus-size actress as the primary love interest in the film. The campaign is being ... significantly affects how and what we think,” Michael Elliot, an award-winning screenwriter and CEO ...
Breaking Medicine News(10 mins):Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:Award-Winning Screenwriter Uses Crowdfunding Campaign to Change Hollywood’s Ideal of Beauty to Include PLUS-SIZE Women 2
... a gene that appears to increase a person,s risk ... of the disease. The gene, abbreviated as MTHFD1L, is ... association study. Details are published September 23 in the ... of researchers was led by Margaret A. Pericak-Vance, PhD, ...
... of motorcycle crashes were 1.5 times more likely to ... though many more of the African-American victims were wearing ... new study by Johns Hopkins researchers. Results of ... August issue of the American Journal of Surgery ...
... Steven Reinberg HealthDay Reporter , THURSDAY, Sept. 23 ... use and texting soared in the space of three years, ... alone caused more than 16,000 deaths in car accidents from ... cell phones and texting while driving rose 28 percent in ...
... Cancer Center have discovered a new cell signaling pathway ... when defective, helps promote the formation of several major ... The new pathway, part of a global DNA damage ... are known to cause cancer because, unchecked, they can ...
... Nursing professor, Dr. Diane Doran, was awarded more than ... safety of over 900,000 Canadians who receive health care ... Patient Safety Institute and its partners announced today the ... of Canada,s leading healthcare researchers. The selected research team ...
... a well-crafted football play designed to block the opposing ... constantly executes complex ,plays, or sequences of events to ... Scientists at the University of Rochester Medical Center recently ... the unwanted enlargement of the heart and a well-known ...
Cached Medicine News:Health News:Team of researchers finds possible new genetic risk for Alzheimer's disease 2Health News:Black motorcyclists -- even in helmets -- more likely to die in crashes 2Health News:Texting Taking a Deadly Toll on Roads 2Health News:Texting Taking a Deadly Toll on Roads 3Health News:UCLA cancer researchers discover new signaling pathway that controls cell development and cancer 2Health News:UCLA cancer researchers discover new signaling pathway that controls cell development and cancer 3Health News:$1 million awarded to Bloomberg Faculty of Nursing-led research team 2Health News:Molecular 'playbook' for halting heart failure risk factor uncovered 2
ASAT (GOT) FS (IFCC mod). For determination of ASAT (GOT) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
... The DRS 2000, a uniquely intelligent system, ... its space saving, 2-level design. Up to 27 ... to give you the flexibility to tailor your ... lab. Two start stations allow for continuous loading; ...
... latest from the leader in automatic slide ... modern approach to slide staining, ending messy ... blood smears, bone marrow and other body ... Aerospray stainer becomes a superb cytocentrifuge with ...
Medicine Products: